Genomma Lab InternacionalB de CV (MEX:LABB) Tariff Resilience Score: 6/10 (As of Jun. 26, 2026)


MEX:LABB Genomma Lab Internacional SAB de CV MEX:LABB
66 GF Score
Price MXN15.04
GF Value MXN17.64
Valuation Modestly Undervalued
! 4 Warning Signs
View Full Analysis

What is Genomma Lab InternacionalB de CV Tariff Resilience Score?

Genomma Lab InternacionalB de CV MEX:LABB +2.59% 66 Tariff Resilience Score is 6 as of Jun. 26, 2026. GuruFocus rates MEX:LABB with a GF Score™ of 66/100 and a GF Value™ of MXN17.64 (Modestly Undervalued). The stock has 4 warning signs investors should review. Among 1,031 Drug Manufacturers companies, Genomma Lab InternacionalB de CV ranks better than 90.98% on this metric.

Genomma Lab InternacionalB de CV has the Tariff Resilience Score of 6, which implies that the company might have Average Resilient.

Genomma Lab InternacionalB de CV has Genomma Lab, a consumer goods company, faces moderate tariff risks due to its international operations. Its ability to shift production and sourcing provides some mitigation against tariff impacts.

Tariff Resilience Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more.

The company's exposure to international trade tariffs based on these criteria:

1. Global supply chain dependencies
2. Manufacturing locations versus sales markets
3. Import/export balance and percentage of revenue
4. Historical impact from previous tariff changes
5. Available mitigation strategies (alternative suppliers, pricing power)
6. Industry-specific tariff exemptions or vulnerabilities

Based on the research, GuruFocus believes Genomma Lab InternacionalB de CV might have Average Resilient.

Genomma Lab InternacionalB de CV  (MEX:LABB) Tariff Resilience Score Explanation

The Tariff Resilience Score ranges from 0 to 10, with 10 as the most resilient. GuruFocus divided Moat Score into following 3 categories:

Tariff Resilience Score Resilience Level
7 - 10Highly Resilient
4 - 6Average Resilient
0 - 3Highly Vulnerable

Genomma Lab InternacionalB de CV Tariff Resilience Score Related Terms

MEX:LABB vs ZTS, UTHR, VTRS: Tariff Resilience Score Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Genomma Lab InternacionalB de CV's Tariff Resilience Score, along with its competitors' market caps and Tariff Resilience Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Genomma Lab InternacionalB de CV Tariff Resilience Score vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Genomma Lab InternacionalB de CV's Tariff Resilience Score distribution charts can be found below:

* The bar in red indicates where Genomma Lab InternacionalB de CV's Tariff Resilience Score falls into.


MEX:LABB
66GF Score
Genomma Lab Internacional SAB de CV MEX:LABB
Tariff Resilience Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Tariff Resilience Score of 6 mean?
Genomma Lab InternacionalB de CV (MEX:LABB) has a Tariff Resilience Score of 6 as of Jun. 26, 2026. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. According to the industry distribution chart, Genomma Lab InternacionalB de CV ranks #93 out of 1031 companies in the Drug Manufacturers industry, placing it in the top 9%.
Is Genomma Lab InternacionalB de CV's Tariff Resilience Score too high?
Genomma Lab InternacionalB de CV's current Tariff Resilience Score is 6. Based on the distribution chart, Genomma Lab InternacionalB de CV ranks #93 out of 1031 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Genomma Lab InternacionalB de CV has a GF Score™ of 66/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Genomma Lab InternacionalB de CV's Tariff Resilience Score compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Genomma Lab InternacionalB de CV ranks #93 out of 1031 companies for Tariff Resilience Score. This places Genomma Lab InternacionalB de CV in the top 9% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Tariff Resilience Score for a Drug Manufacturers company?
A good Tariff Resilience Score depends on the Drug Manufacturers industry context. However, Tariff Resilience Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Tariff Resilience Score mean?
A high Tariff Resilience Score can signal that a stock is expensive relative to its fundamentals. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. Genomma Lab InternacionalB de CV's current Tariff Resilience Score is 6. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Genomma Lab InternacionalB de CV stock overvalued right now?
Based on GuruFocus' analysis, Genomma Lab InternacionalB de CV (MEX:LABB) is currently considered Modestly Undervalued. The stock's GF Value™ is MXN17.64, compared to a current price of MXN15.04 — trading 14.7% below its estimated fair value. The current Tariff Resilience Score is 6. Genomma Lab InternacionalB de CV's overall GF Score™ is 66/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Tariff Resilience Score calculated?
Tariff Resilience Score is calculated from a company's financial statements. For Genomma Lab InternacionalB de CV (MEX:LABB), the current Tariff Resilience Score is 6 as of Jun. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Genomma Lab InternacionalB de CV (MEX:LABB) Overvalued in 2026?

Based on GuruFocus' analysis, Genomma Lab InternacionalB de CV stock appears to be undervalued. The current stock price of MXN15.04 is trading 14.7% below its estimated GF Value™ of MXN17.64. GuruFocus considers Genomma Lab InternacionalB de CV to be Modestly Undervalued.

Key valuation signals for MEX:LABB:

  • Tariff Resilience Score: 6
  • GF Value™: MXN17.64 vs. price of MXN15.04 (14.7% below fair value)
  • GF Score™: 66/100 with 4 warning signs

No single metric tells the full story. See the MEX:LABB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Genomma Lab InternacionalB de CV Business Description

Other Exchanges GNMLF:USAGEKA:Germany
Address Avenida Antonio Dovali Jaime, Number 70, Tower C, Floor 2, Office A. Colonia Santa Fe, Del. Alvaro Obregon, Mexico, MEX, MEX, CP 01210
Genomma Lab Internacional SAB de CV is a specialty and generic drug manufacturer. The company's stated goal is to improve and preserve the health and well-being of people through innovative, safe, and effective products. Genomma operates a wide variety of brands to serve different consumer needs, including pregnancy, pain medication, and deodorant. The company considers merger and acquisition investment as a potential component of its operational growth strategy for expanding its research, development, manufacturing, and marketing capabilities.
66GF Score

Get the complete analysis for MEX:LABB

Tariff Resilience Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN15.04
Price
MXN17.64
GF Value